About Symbio Generrics
Symbio Generrics is a company based in Mumbai (India) founded in 2010 by Salim Sadiq Shaikh and Abhijit Govindrao Kale. Symbio Generrics has raised $12.93 million across 2 funding rounds from investors including Ascent Capital, Aahi Family Trust and Vivek Gupta. The company has 161 employees as of April 09, 2024. Symbio Generrics offers products and services including Active Pharmaceutical Ingredients and Intermediates.
- Headquarter Mumbai, India
- Employees 161 as on 09 Apr, 2024
- Founders Salim Sadiq Shaikh, Abhijit Govindrao Kale
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Symbio Generrics India Private Limited
- Jurisdiction Bangalore South, Karnataka, India
-
Annual Revenue
$48.87 M (USD)0as on Mar 31, 2023
-
Net Profit
$1.96 M (USD)0as on Mar 31, 2023
-
EBITDA
$2.93 M (USD)0as on Mar 31, 2023
-
Total Equity Funding
$12.93 M (USD)
in 2 rounds
-
Latest Funding Round
$12.86 M (USD), Private Equity Round
Mar 30, 2022
-
Investors
Ascent Capital
& 9 more
-
Employee Count
161
as on Apr 09, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Symbio Generrics
Symbio Generrics offers a comprehensive portfolio of products and services, including Active Pharmaceutical Ingredients and Intermediates.
Active Pharmaceutical Ingredients are manufactured and marketed by Symbio Generrics for various therapeutic areas
Intermediates are produced by Symbio Generrics for the development and manufacturing of APIs
Funding Insights of Symbio Generrics
Symbio Generrics has successfully raised a total of $12.93M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $12.86 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Symbio Generrics
Symbio Generrics has secured backing from 10 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Ascent Capital, Aahi Family Trust and Vivek Gupta.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
AscentCapital is engaged in potato farming, grain marketing, and equipment services in Maine.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
VG
Vivek Gupta |
Angel investor, tech entrepreneur, ex-Microsoft, focused on Indian startups
|
Locked | Locked | Locked |
Investor details for Symbio Generrics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Symbio Generrics
Investment portfolio details for Symbio Generrics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Symbio Generrics
Detailed financials for Symbio Generrics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Symbio Generrics Comparisons
Peer comparison for Symbio Generrics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Symbio Generrics
Detailed competitors of Symbio Generrics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Symbio Generrics
Complete news archive for Symbio Generrics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Symbio Generrics
Symbio Generrics was founded in 2010 and raised its 1st funding round 12 years after it was founded.
Symbio Generrics is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Akash Puranik is the current CEO of Symbio Generrics.
Symbio Generrics is a funded company, having raised a total of $12.93M across 2 funding rounds to date.
As of Apr 09, 2024, the latest employee count at Symbio Generrics is 161.
Annual revenue of Symbio Generrics is $48.87M as on Mar 31, 2023.
Symbio Generrics was established in 2010 in Mumbai, India, and operates as a contract development and manufacturing organization in the pharmaceutical sector. Active pharmaceutical ingredients and intermediates are produced for clients through specialized processes. The company is led by co-founders Salim Sadiq Shaikh and Abhijit Govindrao Kale, with Akash Puranik serving as CEO and managing director. Operations are centered on regulatory-compliant manufacturing.
Symbio Generrics offers Active Pharmaceutical Ingredients and Intermediates.
Symbio Generrics has 10 investors. Key investors include Ascent Capital, Aahi Family Trust, Vivek Gupta, Chandan Shetty, and Jayashree Rao.
The valuation of Symbio Generrics is $24.31M as of Mar 2022.